SAINT LOUIS, MO, United States
SAINT LOUIS, MO, United States
SEARCH FILTERS
Time filter
Source Type

Patent
Mediomics, Llc | Date: 2017-07-19

The invention generally provides molecular biosensors with modular epitope binding constructs. The molecular biosensors are useful in several methods including in the identification and quantification of target molecules.


Patent
Mediomics, Llc | Date: 2015-09-11

The invention generally provides molecular biosensors with modular epitope binding constructs. The molecular biosensors are useful in several methods including in the identification and quantification of target molecules.


Patent
Washington University in St. Louis and Mediomics, Llc | Date: 2015-05-22

The present invention provides molecular biosensors capable of signal amplification, and methods of using the molecular biosensors to detect the presence of a target molecule.


Patent
Mediomics, Llc and Washington University in St. Louis | Date: 2015-02-16

The invention generally provides three-component molecular biosensors. The molecular biosensors are useful in several methods including in the identification and quantification of target molecules.


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase II | Award Amount: 997.25K | Year: 2012

Biologic drugs are therapeutic medicinal products engineered from living cells or proteins. The novel introduction of these products has already had an enormous impact on some medical subfields, including rheumatology, cardiology, oncology, and others. Biologics are, however, very complicated to manufacture, requiring stringent sanitary conditions for cell-production and growth. Small threats to production can create enormous complications in the production chain, potentially producing medication shortages. We have successfully completed all tasks in our Phase I project. In the Phase II project, our goal is to develop a fully automated in-process analyzer to monitor the quantity and quality of biologics. The homogeneous assays to be developed include: quantitative antigen-specific antibody assays, affinity assays, glycosylation assays and aggregation assays. The complete system is expected to be beta-tested by third parties, and the system should be ready for commercialization at the end of the project.


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase II | Award Amount: 737.95K | Year: 2012

Early diagnosis of the hepatitis C virus (HCV) infection is crucial for treatment and prevention. PCR screening and ELISA-based assay are currently used to detect viral RNA and HCV antibodies in patient blood samples. There are, however, no commercially available serological assays which can discriminate between acute and chronic HCV infection. In the phase I project, the company developed magnetic bead-based PINCER assay as well as homogeneous PINCER assays for quick detection of anti-HCV IgG and IgM. To continue this project, it is proposed to 1. Validate the magnetic beads-based PINCER assay with patient samples, 2. Develop homogeneous PINCER assays using a complete panel of HCV antigens and validate the assays with clinical samples and 3. Develop and validate PINCER assays for HCV core antigen. It is expected that after successfully implementing the phase II project, the company will provide a unique set of simple, robust and cost-effective screening tools for detection of anti-HCV antibody and antigens for diagnosis of acute and chronic HCV infection


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase II | Award Amount: 969.77K | Year: 2013

Not Available


Patent
Washington University in St. Louis and Mediomics, Llc | Date: 2015-03-30

The present invention encompasses a method for detecting a target comprising a repeating epitope.


Patent
Washington University in St. Louis and Mediomics, Llc | Date: 2014-03-05

The present invention encompasses a method for detecting a target comprising a repeating epitope.


Grant
Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: SBIR | Phase: Phase I | Award Amount: 157.96K | Year: 2016

More than structurally distinct modified nucleosides have been identified and at least of them occur in eukaryotic cells However the functional roles of many other covalent RNA modifications remain poorly characterized or unknown although they are likely to influence RNA properties and functions such as RNA stability trafficking localization activity and patterns of interactions with other molecules Among RNA modifications m A is the most prevalent modified base in mRNA It is a reversible and widespread modification that is primarily located in evolutionarily conserved regions and is particularly enriched near the stop codon Identifying m A residues is challenging The current m A mapping approach methyl RNA immunoprecipitation and sequencing involves the immunoprecipitation of nt long RNA fragments with m A specific antibodies This approach generates m A peaks but it does not identify specific m A residues To solve this problem Dr Samie Jaffrey s laboratory at The Weill Medical School of Cornell University successfully developed a novel approach miCLIP and they mapped m A and m Am residues throughout the transcriptome at single nucleotide resolution However during the development of the miCLIP method they found that different antibodies can produce very different results and the chosen ones are polyclonal antibodies There is thus a need for well characterized recombinant antibodies specifically optimized for the miCLIP method In this project we propose to work with Dr Jaffrey s laboratory to develop single chain variable fragments scFvs specifically selected and optimized for this important methodology In aim we will use the phage display system that has been well established at Mediomics to develop and characterize high affinity scFvs In aim we will screen for the scFvs that are most suitable for the miCLIP method and then the selected scFvs will be evaluated by Dr Jaffrey s laboratory using the miCLIP systems established in his laboratory Success in the Phase I project will provide us with a strong foundation to develop more needed scFv tools for the detection of other RNA modifications at single nucleotide resolution We believe that the availability of these sustainable tools will significantly advance research in this important growing field RNA modifications have been shown to play a role in intellectual disability microcephaly myoclonus epilepsy depression schizophrenia and addiction relevant behaviors In this project unique recombinant antibodies will be developed characterized and validated for the detection of RNA modifications at single nucleotide resolution The availability of these sustainable tools will significantly advance research in this important growing field

Loading Mediomics, Llc collaborators
Loading Mediomics, Llc collaborators